Intravenous versus subcutaneous EPO: is the cost benefit acceptable?
Mario
M
Fraticelli
Marco
M
D'Amico
Ferruccio
F
Conte
D000740:Anemia / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D006801:Humans; D007275:Injections, Intravenous / Q000191:economics; D007279:Injections, Subcutaneous / Q000191:economics; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000191:economics / Q000517:prevention & control*; D006435:Renal Dialysis / Q000009:adverse effects
D011994:Recombinant Proteins; D004921:Erythropoietin